PerkinElmer (NYSE:PKI) sells diagnostic tools and specialized optics for medical and environmental analysis, and had 2007 sales of $1.8 billion. PerkinElmer sells approximately half of all prenatal genetic diagnostics in the US and is currently the only company to offer a complete genetic screening package that test for hereditary diseases and saves umbilical cord blood for potential stem cell use. In 2007, it acquired ViaCell for $296 million to make use of their ViaCord umbical cord blood samples to expand its neonatal and prenatal scanning business.
Currently 90 percent of newborns in the US receive mandatory screening and the passage of two new federal bills favoring genetic screening would expand PerkinElmer's target market. In 2007, PKI launched EcoAnalytix, a new environmental diagnostics platform targeted for developing countries that includes tools to test for food safety, water quality, and biofuel standards. As an international company, favorable foreign exchange rates accounted for 25% of PerkinElmer's revenue growth between 2006-2007.
PerkinElmer has increased its gross sales from $1.5 billion in 2006 to $1.8 billion through acquisitions and the development of international sales. Growth has been particularly strong in China, where sales have increased more than 100% from $46 million in 2006 to $97 million in 2008. PerkinElmer seeks to increase its presence in India through the opening of Ecolytix and the $2 million acquisiton of minority shares of PerkinElmer India. 
|Sales Revenue||Operating Income|
|Sector||Sales Revenue in 2007||% Change (06-07)||Sales Revenue in 2006||% Change (05-06)||Sales Revenue in 2005**|
|Life & Analytical Sciences||$1,327.2||15.96%||$1,144.6||5.87%||$1,081.1|
|Total Sales Revenue||$1,787.3||15.8%||$1,546.4||4.92%||$1,473.8|
PerkinElmer increased its research and development funding by over 14% between 2006 and 2007, but did not did not change the distribution of its funding. In 2007, as in 2006, the company allocates most of its funding to genetic screening within its Life and Analytical Sciences Segment and medical imaging within its Optoelecronics segment.
|Year||Research & Development Spending|
PerkinElmer sells its products in over 150 countries worldwide, but primarily in the United States, United Kingdom, China, France, and Italy. It has opened a regional office in Mumbai in 2007 in order to increase its presence in the developing world. The company is aiming to develop its sales in emerging economies, specifically in China, where its sales have grown more than 100% to $97 million since 2006. 
PerkinElmer has screened over 240 million babies world wide for genetic disorders; more than any other company. Pre-birth or prenatal genetic screening is rapidly advancing in the US and has now become mandatory for nearly 90% of newborn babies in the US. Many of the states which require genetic screening do not screen for all genetic disorders (i.e. Mass., a pioneer in this field, only requires genetic screens in 12 of 29 of the core test areas); however, two new federal bills have been introduced that would mandate more genetic screening. The passage of these bills would expand the market for PerkinElmer's neonatal genetic screening business.
PerkinElmer's Life and Analytic Sciences segment sells analytic tools to measure the impact of human activities on the environment. The company launched a new platform EcoAnalytix in India and China, which includes tools to test for food safety, water quality, and biofuel development. The company cites sales of a food safety test (which tests for the presence of melamine, a contaminant) as the first tangible result of EcoAnalytix, although results of sales have not been published.
60% of PerkinElmer's sales are located outside of the United States, which makes foreign exchange an important part of sales revenues and production costs.  While currency exchange rates are a risk associated with international business, the export-favorable fall of the dollar was responsible for 25% of the increase of sales between 2006 and 2007.
No one competitor competes with PerkinElmer in all of its product and geographic markets. Many of PKI's products incorporate patented technologies, so they have no direct competitors for those products.
While many of its products are comparable to competitors' products, PerkinElmer's one-stop genetic scanning and umbilical blood preservation system is new and unique in the genetic screening market.